抗体偶联药物在肿瘤治疗中的研究进展  

The research progress of antibody-drug conjugates in cancer treatment

作　　者：徐玉怡 曹锦雪 王东凯[1] XU Yuyi;WANG Dongkai(School of Pharmacy,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区：[1]沈阳药科大学药学院,辽宁沈阳110016

出　　处：《中国药剂学杂志（网络版）》2024年第3期107-113,共7页Chinese Journal of Pharmaceutics：Online Edition

摘　　要：抗体—药物偶联物是由特异性的单克隆抗体和高细胞毒性的化学药物通过连接子组合而成,不仅可以解决单克隆抗体临床效果差、毒副作用较大的问题,还能将化学小分子药物特定地靶向到肿瘤细胞,使药物疗效最大化。目前,随着抗体偶联药物的不断发展,在肿瘤的临床治疗应用也逐渐广泛,具有广阔发展前景。Antibody-drug conjugates are a combination of specific monoclonal antibody and highly cytotoxic chemical drug by the linker.ADCs can not only solve the problems of poor clinical effect of monoclonal antibody and large toxic side effects,but also can specifically target chemical small molecule drugs to tumor cells to maximize drug efficacy.At present,with the continuous development of antibody-coupled drugs,the clinical application of cancer treatment is gradually widespread,the future prospects are promising.

关 键 词：抗体偶联药物 肿瘤治疗 单克隆抗体 细胞毒剂 连接子 

分 类 号：R94[医药卫生—药剂学]